Phase II study of biweekly gemcitabine and docetaxel as first-line treatment for advanced disease in non-small cell lung cancer (NSCLC) patients with ECOG performance status 2.

被引：0
|
作者：
Giner, V.
Juan Vidal, O.
Munoz, J., Sr.
Esquerdo, G.
Sanchez-Hernandez, A.
Gomez-Codina, J.
Aparisi, F.
Macia, S.
Lopez Jimenez, A.
Catot, S.
机构：
[1] Hosp Sagunto, Puerto Sangunto, Spain
[2] Hosp Arnau Vilanova, Valencia, Spain
[3] Hosp Doctor Peset, Valencia, Spain
[4] Hosp Clin Benidorm, Benidorm, Spain
[5] Hosp Prov Castellon, Castellon de La Plana, Spain
[6] Hosp La Fe, E-46009 Valencia, Spain
[7] Hosp Virgen de los Lirios, Alcoy, Spain
[8] Hosp Gen Elda, Elda, Spain
[9] Hosp Clin San Juan, Alicante, Spain
[10] Hosp Althaia Xarxa, Manresa, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18083
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18083
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Sequential versus concomitant administration of docetaxel and gemcitabine as first-line treatment of advanced non-small cell lung cancer (NSCLC):: results of a phase II/III randomised study
    Manegold, C.
    Thatcher, N.
    Kortsik, C.
    Koschel, G.
    Spengler, W.
    Mezgar, J.
    Schott von Romer, K.
    Pilz, L.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 326 - 326
  • [22] Phase II study of docetaxel and oxaliplatin in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer (NSCLC).
    Raez, L. E.
    Brito, R.
    Kobina, S.
    Perdekamp, M. G.
    Karr, M.
    Santos, E. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] RANDOMIZED PHASE II TRIAL OF SAFETY OF BIWEEKLY DOCETAXEL/CISPLATIN VS GEMCITABINE/CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WHO ARE ELDERLY OR POOR PERFORMANCE STATUS
    Kim, Hoon K.
    Jang, Joung-Soon
    Cho, Byoung Chul
    Lee, Kyung Hee
    Yun, Hwan Jung
    Woo, In Sook
    Kim, Chi Hong
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S573 - S573
  • [24] Phase II study of gemcitabine plus oxaliplatin as first-line treatment in elderly or unfit patients with advanced non-small cell lung cancer (NSCLC). The ACROSS Study
    Domenech, Montse
    Losa, Ferran
    Blanco, Remei
    Nogue, Miquel
    Montesinos, Jesus
    Mesia, Carles
    Gallardo, Enrique
    Perez de Olaguer, Joaquim
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 177 - 177
  • [25] Weekly docetaxel-gemcitabine as first-line treatment in advanced non-small cell lung cancer: Preliminary results of a phase II study.
    Kalmadi, SR
    Mekhail, T
    Adelstein, D
    Giannini, C
    Peereboom, D
    Olencki, T
    Davis, M
    Bukowski, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 675S - 675S
  • [26] Docetaxel/gemcitabine vs. cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC):: Results of a randomised phase II trial
    Binder, D
    Schweisfurth, H
    Grah, C
    Schäper, C
    Temmesfeld-Wollbrück, B
    Siebert, G
    Suttorp, N
    Beinert, T
    [J]. LUNG CANCER, 2005, 49 : S237 - S237
  • [27] Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer
    Chiappori, A
    Simon, G
    Williams, C
    Haura, E
    Rocha-Lima, C
    Wagner, H
    Bepler, G
    Antonia, S
    [J]. ONCOLOGY, 2005, 68 (4-6) : 382 - 390
  • [28] A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer
    Eleni M. Karapanagiotou
    Adrianni Charpidou
    Ifigenia Tzannou
    Kalliopi Dilana
    Elias Kotteas
    Ioannis Tourkantonis
    Epaminondas Kosmas
    Aspasia Provata
    Kostas Syrigos
    [J]. Medical Oncology, 2008, 25 : 303 - 308
  • [29] A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer
    Karapanagiotou, Eleni M.
    Charpidou, Adrianni
    Tzannou, Ifigenia
    Dilana, Kalliopi
    Kotteas, Elias
    Tourkantonis, Ioannis
    Kosmas, Epaminondas
    Provata, Aspasia
    Syrigos, Kostas
    [J]. MEDICAL ONCOLOGY, 2008, 25 (03) : 303 - 308
  • [30] A Phase II Study of Weekly Docetaxel-Cisplatin As First-Line Treatment for Advanced Non-small Cell Lung Cancer
    Binder, Daniel
    Hackenthal, Matthias
    Graseck, Lutz
    Schweisfurth, Hans
    Schaeper, Christoph
    Kruell, Matthias
    Temmesfeld-Wollbrueck, Bettina
    Suttorp, Norbert
    Suttorp, Thomas
    Beinert, Thomas
    Hellriegel, Klaus-Peter
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : 1144 - 1147
12345